Suppression of gastric cancer cell growth by targeting the β‐catenin/T‐cell factor pathway

Abstract

Selective targeting of gastric cancer cells with the activated beta-catenin pathway may be a novel and effective therapy in gastric cancer. Combination of this gene-therapy approach with standard therapy may improve efficacy and reduce toxicity.